You have 9 free searches left this month | for more free features.

Fruquintinib

Showing 1 - 25 of 97

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Fruquintinib in the Cross-line Treatment of Refractory mCRC

Recruiting
  • Fruquintinib
  • Metastatic Colorectal Cancer
  • Wuhan, Hubei, China
  • +2 more
Oct 23, 2023

TAS-102 in Combination With Regorafenib or Fruquintinib for

Not yet recruiting
  • TAS 102
  • +3 more
  • (no location specified)
Aug 7, 2023

Advanced Colorectal Cancer Trial in Hangzhou (Fruquintinib Combined With Chemotherapy)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Fruquintinib Combined With Chemotherapy
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jun 29, 2023

Esophageal Squamous Cell Carcinoma Trial (Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin
  • (no location specified)
Aug 17, 2023

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Recruiting
  • Gastric Cancer
  • Fruquintinib, TAS102
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Metastatic Colorectal Cancer Trial in Nanchang (Fruquintinib)

Recruiting
  • Metastatic Colorectal Cancer
  • Fruquintinib
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Nov 1, 2023

Hepatocellular Carcinoma Trial in Hangzhou (Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Fruquintinib
  • +2 more
  • Hangzhou, Zhejiang, China
    Guoliang Shao
Aug 1, 2023

Gastric Cancer Trial (Fruquintinib)

Not yet recruiting
  • Gastric Cancer
  • Fruquintinib
  • (no location specified)
Oct 17, 2023

Colorectal Cancer Metastatic Trial in Guangzhou (Fruquintinib)

Recruiting
  • Colorectal Cancer Metastatic
  • Fruquintinib
  • Guangzhou, Guangdong, China
    Colorectal Department,SunYat-sen University Cancer Center
Aug 28, 2023

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Colorectal Cancer Trial in Shanghai (Fruquintinib+mFOLFOX6/FOLFIRI)

Recruiting
  • Colorectal Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 23, 2023

Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal

Completed
  • Colorectal Cancer
  • Fruquintinib combined with anti-PD-1 antibodies
  • ChangSha, Hunan, China
    Hunan Cancer Hospital
Aug 27, 2023

Fruquintinib With PD-1 Inhibitors Versus TAS-102 With

Completed
  • Metastatic Colorectal Adenocarcinoma
  • Fruquintinib
  • +3 more
  • Changsha, Hunan, China
    Hunan Cancer hospital
Sep 2, 2023

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)

Recruiting
  • HER2-positive Gastric Cancer
  • Immunotherapy
  • Disitamab Vedotin combined with fruquintinib and Tislelizumab
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2023

Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)

Active, not recruiting
  • Stomach Neoplasms
  • Shanghai, China
    Renji Hospital
Apr 3, 2023

Colorectal Cancer Trial in Changsha (fruquintinib and FOLFIRI)

Not yet recruiting
  • Colorectal Cancer
  • fruquintinib and FOLFIRI
  • Changsha, Hunan, China
    Hunan Cancer hospital
Apr 24, 2023

Gastric Cancer, GastroEsophageal Cancer, Fruquintinib Trial in Nanning (Fruquintinib + SOX)

Recruiting
  • Gastric Cancer
  • +3 more
  • Fruquintinib + SOX
  • Nanning, China
    Guangxi Medical University Cancer Hospital
Dec 2, 2022

First-line Treatment of Non-clear Renal Cell Carcinoma Trial (Fruquintinib combined with Serplulimab)

Not yet recruiting
  • First-line Treatment of Non-clear Renal Cell Carcinoma
  • Fruquintinib combined with Serplulimab
  • (no location specified)
Apr 16, 2023

Rectal Cancer Trial in Chengdu (drug, radiation, procedure)

Recruiting
  • Rectal Cancer
  • Fruquintinib
  • +3 more
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Mar 8, 2023

Gastric Cancer Trial (Fruquintinib, Irinotecan)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Dec 6, 2022

Colorectal Cancer Trial in Shanghai (serplulimab, Fruquintinib)

Not yet recruiting
  • Colorectal Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 13, 2023

Unresectable/Metastatic Colorectal Cancer Trial in Guangzhou (Fruquintinib plus camrelizumab and capecitabine)

Recruiting
  • Unresectable/Metastatic Colorectal Cancer
  • Fruquintinib plus camrelizumab and capecitabine
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Nov 19, 2023

Metastatic Colorectal Cancer Trial in Wuhan (SBRT, Fruquintinib, Cadonilimab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • SBRT, Fruquintinib, Cadonilimab
  • Wuhan, Hubei, China
    Cancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023

Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma Trial (fruquintinib, Envafolimab)

Not yet recruiting
  • Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma
  • (no location specified)
Jul 10, 2023